JUVEDERM® SKINVIVE

Juvederm® Skinvive — Understanding the FDA-Approved HA Gel Implant for Skin Smoothness Practitioners looking to buy Juvederm® Skinvive are increasingly considering it for patients presenting with concerns about cheek skin smoothness rather than volumetric deficiency. Skinvive by Juvederm® was the first FDA‑approved hyaluronic acid gel implant indicated to improve cheek skin smoothness.  Practitioners seeking clinical protocol information may contact Medical Spa Rx for product guidance and availability.  Why Skinvive by Juvederm®? Filling the Skin Quality Gap Skinvive by Juvederm® addresses a specific clinical gap between topical skincare and structural dermal filler injections. Its benefits are centered on skin quality rather than structural correction: improved cheek skin smoothness, enhanced facial tissue hydration, increased radiance, and reduction in fine surface lines — without volumetric change. Ideal candidates present with dull or uneven facial texture, crepey or rough facial tissue, or reduced face smoothness without midface volume loss. Skinvive is not a substitute for volumizing fillers; it serves as a complementary skin-quality protocol for patients with intact facial structure but compromised dermal hydration and surface texture. This positions Skinvive as a distinct option within the injectable aesthetic category. Practitioners can integrate it alongside other modalities when the clinical objective is skin quality rather than facial reshaping. What Is Skinvive by Juvederm®? Formulation & FDA Status Skinvive by Juvederm® uses the VYC-12L formulation: cross-linked hyaluronic acid at 12 mg/mL with 0.3% lidocaine, stabilized using BDDE (1,4-butanediol diglycidyl ether) cross-linking chemistry. This produces a smooth, viscoelastic intradermal gel designed specifically for hydration rather than structural augmentation — with lower gel stiffness and cohesivity compared with volumizing VYCROSS fillers.  Regulatory & Product Highlights Manufacturer: Allergan Aesthetics (AbbVie) FDA approval: 2023; first product indicated for improving skin smoothness of the cheeks in adults aged 21 and older Device classification: Prescription-only; restricted to licensed aesthetic practitioners International availability: Marketed as Juvederm® Volite in CE-marked markets; indication scope and approved treatment areas vary by region How Juvederm® Skinvive Works Skinvive works by delivering cross-linked hyaluronic acid into the dermis, where HA molecules attract and retain water within the extracellular matrix. Here, Skinvive increases dermal hydration and improves cheek skin texture at the tissue level. The microdroplet technique places small, evenly distributed deposits throughout the cheek dermis, achieving diffuse hydration of facial tissue rather than focal projection or contour change. BDDE cross-linking extends the degradation time of the HA matrix compared with non-cross-linked HA solutions, thereby supporting sustained hydration. Clinical outcomes are associated with improved face smoothness, radiance, and skin quality, not structural augmentation. U.S. pivotal data show improvement for at least six months, while some international VYC‑12 studies (Volite) report hydration benefits up to nine months after repeat treatment. Skinvive by Juvederm® Reviews, Duration & Clinical Evidence When evaluating Skinvive by Juvederm® reviews, practitioners should rely on controlled clinical data rather than anecdotal sources. Three published studies support its use: US Pivotal Trial 57.9% ACSS responder rate at one month vs. 4.5% in the no-treatment control group (p < 0.001) 55.6% of treated participants maintained response at six months After repeat treatment at six months: 68.5% responder rate at one month post-repeat Patient-Reported Outcomes FACE-Q Satisfaction with Skin scores: 34.9 at baseline → 66.8 at one month 78.4% satisfied with skin hydration at one month vs. 23.7% at baseline 74.4% satisfied with radiance at one month vs. 11.1% at baseline European Prospective Study Studied VYC-12 without lidocaine across cheeks and forehead Improvements in skin topography, fine lines, and hydration observed through nine months following repeat treatment Consistent with longer maintenance intervals seen internationally under the Volite designation Skinvive Juvederm® before-and-after outcomes reflect improved cheek skin smoothness and radiance, and reduced fine-line visibility, not volumetric change. For the U.S. indication, clinical data demonstrate improvement for up to 6 months; many clinicians consider maintenance at 6-month intervals based on patient response. Administration, Safety & Storage Juvederm® Skinvive injection is delivered using a microdroplet intradermal technique, with small deposits placed evenly across the cheek region by a trained aesthetic practitioner. Uniform distribution and consistent injection depth are key to achieving the diffuse hydration effect the product is designed for. A typical treatment session takes 30–45 minutes, and most protocols schedule maintenance at six-month intervals. Side effects are generally mild and in line with what practitioners expect from the HA filler class: Swelling, bruising, erythema, tenderness, and injection-site discomfort Most reactions are transient and self-resolving Serious but rare risks require standard precautionary measures: Vascular occlusion, delayed inflammatory reactions, and hypersensitivity events Hyaluronidase should be on hand during every treatment session Contraindicated in patients with hypersensitivity to hyaluronic acid or lidocaine, and in the presence of active infection or inflammation at the treatment site Storage  2–25°C; do not freeze; protect from direct sunlight. Review full prescribing information before administration. Citations Alexiades M, Palm MD, Kaufman-Janette J, Papel I, Cross SJ, Abrams S, Chawla S. A randomized, multicenter, evaluator-blind study to evaluate the safety and effectiveness of VYC-12L treatment for skin quality improvements. Dermatol Surg. 2023;49(7):682-688. doi:10.1097/DSS.0000000000003802 Niforos F, Ogilvie P, Cavallini M, et al. VYC-12 injectable gel is safe and effective for improvement of facial skin topography: a prospective study. Clin Cosmet Investig Dermatol. 2019;12:791-798. doi:10.2147/CCID.S216222 Kablik J, Monheit GD, Yu L, Chang G, Gershkovich J. Comparative physical properties of hyaluronic acid dermal fillers. Dermatol Surg. 2009;35(Suppl 1):302-312. doi:10.1111/j.1524-4725.2008.01046.x Premarket Approval (PMA) P110033S059. US Food and Drug Administration. https://www.accessdata.fda.gov/cdrh_docs/pdf11/P110033S059C.pdf. Published 2023. Chiu A, Montes JR, Munavalli G, Shamban A, Chawla S, Abrams S. Improved patient satisfaction with skin after treatment of cheek skin roughness and fine lines with VYC-12L: Participant-Reported outcomes from a prospective, randomized study. Aesthetic Surgery Journal. 2023;43(11):1367-1375. doi:10.1093/asj/sjad111 For licensed medical professionals only. This content is for informational purposes only and does not constitute medical advice.